company background image
2550 logo

Changzhou Qianhong BiopharmaLTD SZSE:002550 Stock Report

Last Price

CN¥4.91

Market Cap

CN¥6.3b

7D

-4.7%

1Y

-16.5%

Updated

28 Mar, 2024

Data

Company Financials +

Changzhou Qianhong Biopharma CO.,LTD

SZSE:002550 Stock Report

Market Cap: CN¥6.3b

2550 Stock Overview

Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China.

2550 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance1/6
Financial Health6/6
Dividends5/6

Changzhou Qianhong Biopharma CO.,LTD Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Changzhou Qianhong BiopharmaLTD
Historical stock prices
Current Share PriceCN¥4.91
52 Week HighCN¥6.34
52 Week LowCN¥4.20
Beta0.11
1 Month Change-5.03%
3 Month Change-16.50%
1 Year Change-16.50%
3 Year Change24.62%
5 Year Change-4.85%
Change since IPO0.15%

Recent News & Updates

Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Mar 24
Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Recent updates

Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Mar 24
Does Changzhou Qianhong BiopharmaLTD (SZSE:002550) Have A Healthy Balance Sheet?

Shareholder Returns

2550CN PharmaceuticalsCN Market
7D-4.7%-4.3%-4.9%
1Y-16.5%-11.8%-16.6%

Return vs Industry: 002550 underperformed the CN Pharmaceuticals industry which returned -11.8% over the past year.

Return vs Market: 002550 matched the CN Market which returned -16.6% over the past year.

Price Volatility

Is 2550's price volatile compared to industry and market?
2550 volatility
2550 Average Weekly Movement5.3%
Pharmaceuticals Industry Average Movement7.0%
Market Average Movement8.2%
10% most volatile stocks in CN Market11.5%
10% least volatile stocks in CN Market5.1%

Stable Share Price: 002550 has not had significant price volatility in the past 3 months.

Volatility Over Time: 002550's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19711,102Ke Wanghttps://www.qhsh.com.cn

Changzhou Qianhong Biopharma CO.,LTD manufactures and distributes polysaccharide and protease drugs in China. The company offers its products in the form of tablets, hard capsules, lyophilized powder and lyophilized powder injections, small-volume injections, and raw materials. It provides enzymes, including pancreatic kininogenase series, asparaginase series, and compound digestive enzyme capsule II; and polysaccharides products, such as nadroparin calcium, enoxaparin sodium, dalteparin sodium, and asparaginase and heparin sodium.

Changzhou Qianhong Biopharma CO.,LTD Fundamentals Summary

How do Changzhou Qianhong BiopharmaLTD's earnings and revenue compare to its market cap?
2550 fundamental statistics
Market capCN¥6.28b
Earnings (TTM)CN¥252.87m
Revenue (TTM)CN¥2.12b

24.8x

P/E Ratio

3.0x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2550 income statement (TTM)
RevenueCN¥2.12b
Cost of RevenueCN¥1.26b
Gross ProfitCN¥863.86m
Other ExpensesCN¥610.99m
EarningsCN¥252.87m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

Apr 26, 2024

Earnings per share (EPS)0.20
Gross Margin40.74%
Net Profit Margin11.92%
Debt/Equity Ratio0.8%

How did 2550 perform over the long term?

See historical performance and comparison

Dividends

2.4%

Current Dividend Yield

62%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.